

Date and Time: *21 June 2013, 10.00 – 15.20*

Minutes: Final

Guideline Development Group Meeting

Place: *NICE Offices
Piccadilly Plaza
Manchester*

Present: Damien Longson (Chair)
Natasha Jacques (NJ)
Amanda Adler (AA)
Natasha Marsland (NM)
Anne Fittock (AF)
Prunella Neale (PN)
Ian Lewin (IL)
Sailesh Sankar (SS)
Maria Cowell (MC)
Jonathan Roddick (JR)

Apologies: Mohammed Roshan (MR)
Yvonne Johns (YJ)

In attendance:

NICE Staff:

Abitha Senthinathan (AS)
Stephanie Mills (SM)
Mike Heath (MH)
Robby Richey (RR)
Steven Ward (SWard)
Toni Tan (TT)

NICE Staff apologies:

Gabriel Rogers (GR)
Jenny Kendrick (JK)
Clifford Middleton (CM)

Observers:

Laura Martinez (LM) - NICE		
----------------------------	--	--

Notes

1. DL welcomed the group to the third meeting of this GDG. Apologies were received from *YL, MR, GR, JK and CM*. The Chair asked all GDG members to declare any relevant conflicts of interest. All declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of

Notes

this guideline beyond those which had previously been declared.

DL asked whether the group agreed that the minutes of the previous meeting were a clear and accurate record. The minutes were agreed by all with no amendments to be made. The GDG heard that the objectives of the meeting would be to look at the evidence on self-monitoring of blood glucose levels in people with type 2 diabetes controlled by diet, oral medication and insulin.

SM gave the GDG a brief update on joint working between the diabetes guidelines.

2. AS presented the evidence on self-monitoring in people with type 2 diabetes. The GDG considered the included studies for this question. The group discussed issues such as the consistency of the evidence, the study populations, clinical and statistical significance and the potential psychological benefits and disadvantages of self-monitoring. The GDG also discussed DVLA guidance on self-monitoring.
3. SWard presented the health economic literature which met the inclusion criteria for the self-monitoring evidence review. SWard informed the group that country where the study was conducted and costs would be very important factors to consider in the health economic literature. The GDG discussed health economic issues in relation to the clinical evidence presented.
4. Following lunch, the GDG returned to agree the clinical and health economic evidence statements for self-monitoring. The GDG then continued their discussions and made recommendations based on the evidence presented and their group expertise.
5. AS gave some further background on network meta-analyses and showed the GDG what some of the potential networks might look like for the review question on pharmacological management. RR also gave an update on the review work for target values for HbA1c to be presented at the next GDG meeting.
6. There was no further business to discuss and DL thanked the group for their attendance and input. SM reminded the group of the date of the next meeting and which review question would be presented.

Date, time and venue of the next meeting

Wed 4 & Thurs 5 September 2013 – NICE Offices, Manchester